A rapid near patient testing system for the detection of microbial pathogens in blood
Lead Participant:
MAST GROUP LIMITED
Abstract
The detection and diagnosis of healthcare associated infections in the critical care environment is extremely challenging. In the UK alone, there are over 42,000 HCAI sepsis episodes annually.
Existing culture tests lack the sensitivity and speed necessary to effect time-critical, life-saving clinical decisions needed for safe and personalised patient care. Combining both existing and novel technologies, this will be the first nucleic acid based amplification platform that has been designed for the immediate clinical needs within critical care environments. Bringing novel technology solutions to the patient, will allow clinicians to adopt innovative approaches to patient management to improve survival, safety, patient experience and cost efficiency during the management of patients with suspected life-threatening infections.
Existing culture tests lack the sensitivity and speed necessary to effect time-critical, life-saving clinical decisions needed for safe and personalised patient care. Combining both existing and novel technologies, this will be the first nucleic acid based amplification platform that has been designed for the immediate clinical needs within critical care environments. Bringing novel technology solutions to the patient, will allow clinicians to adopt innovative approaches to patient management to improve survival, safety, patient experience and cost efficiency during the management of patients with suspected life-threatening infections.
Lead Participant | Project Cost | Grant Offer |
---|---|---|
MAST GROUP LIMITED | £840,182 | £ 232,058 |
  | ||
Participant |
||
HEALTH PROTECTION AGENCY | £282,280 | £ 141,140 |
UK HEALTH SECURITY AGENCY | ||
THE UNIVERSITY OF MANCHESTER | £376,099 | £ 376,099 |
INNOVATE UK |
People |
ORCID iD |
Liz Gillies (Project Manager) |